modelJ04AK05
Extends from Pharmacokinetic.Models.PK_3C_enteral.
Information
| name: | Bedaquiline | |
| ATC code: | J04AK05 | route: | oral |
| compartments: | 3 | |
| dosage: | 400 | mg |
| volume of distribution: | 16400 | L |
| clearance: | 2.67 | L/h |
| other parameters in model implementation | ||
Bedaquiline is a diarylquinoline antimycobacterial agent used for the treatment of multidrug-resistant tuberculosis (MDR-TB). It acts by inhibiting the mycobacterial ATP synthase enzyme and has been approved for use in combination therapy for MDR-TB in adults and some pediatric populations. Bedaquiline is currently approved by regulatory agencies including the FDA and EMA.
Pharmacokinetics
Population pharmacokinetics in adult patients with multidrug-resistant pulmonary tuberculosis, generally healthy except for TB, mixed sex, studied after oral administration.
References
Zhu, H, et al., & Lu, Y (2021). Population pharmacokinetics of bedaquiline in patients with drug-resistant TB. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 25(12) 1006–1012. DOI:10.5588/ijtld.21.0158 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34886931
Tanneau, L, et al., & Svensson, EM (2022). Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. Clinical pharmacokinetics 61(8) 1177–1185. DOI:10.1007/s40262-022-01133-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35668346
Maloney, SE, et al., & Hickey, AJ (2023). Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration. Pharmaceuticals (Basel, Switzerland) 16(5) –. DOI:10.3390/ph16050729 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37242512
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
| Pharmacolibrary.Types.Volume | Vdp2 (from PK_3C) | Vdp2PerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | Vdp2PerKg (from PK_3C) | 0.9 | Volume of distribution peripheral 2 (l/kg) |
| Pharmacolibrary.Types.VolumeFlowRate | k13 (from PK_3C) | 1 | intercompartmental 1-3 clearance (l/min) |
| Pharmacolibrary.Types.VolumeFlowRate | k31 (from PK_3C) | 1 | intercompartmental 3-1 clearance (l/min) |
| Pharmacolibrary.Types.TransferRate | ka (from PK_3C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_3C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) | ||
| Interfaces.ConcentrationPort_b | perihperal2Cport (from PK_3C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral2 (from PK_3C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral1 (from PK_3C) | ||
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer1 (from PK_3C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)